Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases

References

• Cooper EE, Pisano CE, Shapiro SC. Cutaneous manifestations of “lupus”: systemic lupus erythematosus and beyond. Int J Rheumatol. 2021;2021:6610509. doi:10.1155/2021/6610509
   PubMed Web of Science ®Google Scholar
• Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology E-Book. Elsevier Health Sciences; 2012.
   Google Scholar
• Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2018;32(2):188–205. doi:10.1016/j.berh.2018.09.004
   PubMed Web of Science ®Google Scholar
• Baek YS, Park SH, Baek J, Roh JY, Kim HJ. Cutaneous lupus erythematosus and its association with systemic lupus erythematosus: a nationwide population-based cohort study in Korea. J Dermatol. 2020;47(2):163–165. doi:10.1111/1346-8138.15162
   PubMed Web of Science ®Google Scholar
• Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Arthritis Res Ther. 2015;17(1):182. doi:10.1186/s13075-015-0706-2
   PubMed Web of Science ®Google Scholar
• Joseph M. Overview of cutaneous lupus erythematosus. UpToDate; 2022. Available from: https://www.uptodate.com/contents/overview-of-cutaneous-lupus-erythematosus?search=cutaneous%20lupus&source=search_result&selectedTitle=1~141&usage_type=default&display_rank=1#H538170103. Accessed October 20, 2022.
   Google Scholar
• Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations. Dermatological, systemic and laboratory findings in 191 patients. Dermatol Basel Switz. 1995;190(4):277–283. doi:10.1159/000246716
   PubMed Web of Science ®Google Scholar
• Okon LG, Werth VP. Cutaneous Lupus Erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391–404. doi:10.1016/j.berh.2013.07.008
   PubMed Web of Science ®Google Scholar
• Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48-49:14–19. doi:10.1016/j.jaut.2014.01.021
   PubMed Web of Science ®Google Scholar
• Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol. 2009;10(6):365–381. doi:10.2165/11310780-000000000-00000
   PubMed Web of Science ®Google Scholar
• Ng PP, Tan SH, Koh ET, Tan T. Epidemiology of cutaneous lupus erythematosus in a tertiary referral centre in Singapore. Australas J Dermatol. 2000;41(4):229–233. doi:10.1046/j.1440-0960.2000.00443.x
   PubMedGoogle Scholar
• Oh EH, Kim EJ, Ro YS, Ko JY. Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. J Dermatol. 2018;45(4):436–443. doi:10.1111/1346-8138.14233
   PubMed Web of Science ®Google Scholar
• He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30(5):490–497. doi:10.1097/BOR.0000000000000522
   PubMed Web of Science ®Google Scholar
• Michaelis TC, Sontheimer RD, Lowe GC. An update in drug-induced subacute cutaneous lupus erythematosus. Dermatol Online J. 2017;23(3):13030/qt55x42822.
   PubMedGoogle Scholar
• Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301(1):99–105. doi:10.1007/s00403-008-0895-5
   PubMed Web of Science ®Google Scholar
• Marzano AV, Tavecchio S, Menicanti C, Crosti C. Drug-induced lupus erythematosus. Ital Dermatol E Sifilogr. 2014;149(3):301–309.
   Google Scholar
• Laurinaviciene R, Sandholdt LH, Bygum A. Drug-induced cutaneous lupus erythematosus: 88 new cases. Eur J Dermatol EJD. 2017;27(1):28–33. doi:10.1684/ejd.2016.2912
   PubMed Web of Science ®Google Scholar
• Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009;301(1):65–70. doi:10.1007/s00403-008-0890-x
   PubMed Web of Science ®Google Scholar
• Figueredo Zamora E, Callen JP, Schadt CR. Drug-induced subacute cutaneous lupus erythematosus associated with Abatacept. Lupus. 2021;30(4):661–663. doi:10.1177/0961203320981146
   PubMed Web of Science ®Google Scholar
• Tebbe B, Mansmann U, Wollina U, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol. 1997;77(4):305–308. doi:10.2340/0001555577305308
   PubMed Web of Science ®Google Scholar
• Wallace E. Subacute Cutaneous Lupus Erythematosus (SCLE) Workup: approach Considerations, Laboratory Studies, Serologic Testing. Medscape; 2020. Available from: https://emedicine.medscape.com/article/1065657-workup#c8. Accessed May 30, 2022.
   Google Scholar
• Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol. 1994;21(9):1665–1669.
   PubMed Web of Science ®Google Scholar
• McDaniel B, Sukumaran S, Koritala T, Tanner LS. Discoid Lupus Erythematosus. StatPearls Publishing; 2022. Available from:. http://www.ncbi.nlm.nih.gov/books/NBK493145/. Accessed May 30, 2022.
   Google Scholar
• Inamadar AC. Perforation of paper with pen: simple technique to explain the carpet tack sign in discoid lupus erythematosus. J Am Acad Dermatol. 2019;81(6):e159–e160. doi:10.1016/j.jaad.2019.03.039
   PubMed Web of Science ®Google Scholar
• Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012;166(1):29–35. doi:10.1111/j.1365-2133.2011.10610.x
   PubMed Web of Science ®Google Scholar
• Rangel LK, Villa-Ruiz C, Lo K, et al. Clinical Characteristics of Lupus Erythematosus Panniculitis/Profundus: a Retrospective Review of 61 Patients. JAMA Dermatol. 2020;156(11):1264–1266. doi:10.1001/jamadermatol.2020.2797
   PubMed Web of Science ®Google Scholar
• Hedrich CM, Fiebig B, Hauck FH, et al. Chilblain lupus erythematosus--a review of literature. Clin Rheumatol. 2008;27(8):949–954. doi:10.1007/s10067-008-0942-9
   PubMed Web of Science ®Google Scholar
• Fiehn C. . Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?. Curr Rheumatol Rep. 2017;19(10):61. doi:10.1007/s11926-017-0689-x
   PubMed Web of Science ®Google Scholar
• Liu E, Daze RP, Moon S. Tumid Lupus Erythematosus: a Rare and Distinctive Variant of Cutaneous Lupus Erythematosus Masquerading as Urticarial Vasculitis. Cureus. 2020;12:5. doi:10.7759/cureus.8305
   Web of Science ®Google Scholar
• Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889–894. doi:10.1111/j.0022-202X.2005.23889.x
   PubMed Web of Science ®Google Scholar
• Klein RS, Morganroth PA, Werth VP. Cutaneous Lupus and the CLASI Instrument. Rheum Dis Clin North Am. 2010;36(1):33–51. doi:10.1016/j.rdc.2009.12.001
   PubMed Web of Science ®Google Scholar
• Bielsa I, Herrero C, Collado A, Cobos A, Palou J, Mascaró JM. Histopathologic findings in cutaneous lupus erythematosus. Arch Dermatol. 1994;130(1):54–58.
   PubMedGoogle Scholar
• Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP. Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 2009;31(1):61–67. doi:10.1097/DAD.0b013e31818520e1
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686. doi:10.1002/art.34473
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Gladman DD. Clinical manifestations and diagnosis of systemic lupus erythematosus in adults. UpToDate; 2022. Available from: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-systemic-lupus-erythematosus-in-adults?search=cutaneous%20lupus&topicRef=4666&source=see_link#H4. Accessed October 20, 2022
   Google Scholar
• Lu Q, Long H, Chow S, et al. Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus. J Autoimmun. 2021;123:102707. doi:10.1016/j.jaut.2021.102707
   PubMed Web of Science ®Google Scholar
• Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011;64(1):37–48. doi:10.1016/j.jaad.2009.12.053
   PubMed Web of Science ®Google Scholar
• Chasset F, Francès C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015;72(4):634–639. doi:10.1016/j.jaad.2014.12.025
   PubMed Web of Science ®Google Scholar
• Jessop S, Whitelaw DA, Grainge MJ, Jayasekera P. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2017;5:CD002954. doi:10.1002/14651858.CD002954.pub3
   PubMed Web of Science ®Google Scholar
• Roenigk HH, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis. 1980;25(3):281–285.
   PubMed Web of Science ®Google Scholar
• Liang JY, Xiong QY, Liang XD, et al. Successful treatment of facial localized discoid lupus erythematosus with intralesional betamethasone: a report of three cases. Dermatol Ther. 2020;33(3):e13389. doi:10.1111/dth.13389
   PubMed Web of Science ®Google Scholar
• Chasset F, Bouaziz JD, Costedoat-Chalumeau N, Francès C, Arnaud L. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol. 2017;177(1):188–196. doi:10.1111/bjd.15312
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20–28. doi:10.1136/ard.2008.101766
   PubMed Web of Science ®Google Scholar
• Presto JK, Werth VP. Cutaneous Lupus Erythematosus: current Treatment Options. Curr Treat Options Rheumatol. 2016;2(1):36–48. doi:10.1007/s40674-016-0033-z
   Google Scholar
• Riley K, Schwager Z, Stern M, Vleugels RA, Femia A. Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. JAMA Dermatol. 2019;155(4):491–493. doi:10.1001/jamadermatol.2018.5212
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Costenbader KH, Desmarais J, et al. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis Rheumatol Hoboken NJ. 2021;73(6):908–911. doi:10.1002/art.41683
   PubMed Web of Science ®Google Scholar
• Desmarais J, Rosenbaum JT, Costenbader KH, et al. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. Arthritis Rheumatol. 2021;73(12):2151–2160. doi:10.1002/art.41934
   PubMed Web of Science ®Google Scholar
• Sigges J, Biazar C, Landmann A, et al. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev. 2013;12(7):694–702. doi:10.1016/j.autrev.2012.10.005
   PubMed Web of Science ®Google Scholar
• Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153(1):157–162. doi:10.1111/j.1365-2133.2005.06552.x
   PubMed Web of Science ®Google Scholar
• Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65(4):717–721.e2. doi:10.1016/j.jaad.2010.08.011
   PubMed Web of Science ®Google Scholar
• Mok CC. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol. 2007;36(5):329–337. doi:10.1080/03009740701607042
   PubMed Web of Science ®Google Scholar
• Keyes E, Jobanputra A, Feng R, et al. Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: a cohort study. J Am Acad Dermatol. 2022;87(2):447–448. doi:10.1016/j.jaad.2021.09.017
   PubMed Web of Science ®Google Scholar
• Ordi-Ros J, Cortés F, Cucurull E, Mauri M, Buján S, Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol. 2000;27(6):1429–1433.
   PubMed Web of Science ®Google Scholar
• Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012;14(6):R265. doi:10.1186/ar4111
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with Acitretin and hydroxychloroquine. Br J Dermatol. 1992;127(5):513–518. doi:10.1111/j.1365-2133.1992.tb14851.x
   PubMed Web of Science ®Google Scholar
• Al-Mutairi N, Rijhwani M, Nour-Eldin O. Hypertrophic lupus erythematosus treated successfully with Acitretin as monotherapy. J Dermatol. 2005;32(6):482–486. doi:10.1111/j.1346-8138.2005.tb00785.x
   PubMed Web of Science ®Google Scholar
• Iaccarino L, Bettio S, Reggia R, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. 2017;69(1):115–123. doi:10.1002/acr.22971
   PubMed Web of Science ®Google Scholar
• Torrente-Segarra V, Peramiquel L, Bonet M. Belimumab in subacute cutaneous lupus erythematosus. Lupus. 2021;30(12):2017–2018. doi:10.1177/09612033211033989
   PubMed Web of Science ®Google Scholar
• Vashisht P, Borghoff K, O’Dell JR, Hearth-Holmes M. Belimumab for the treatment of recalcitrant cutaneous lupus. Lupus. 2017;26(8):857–864. doi:10.1177/0961203316682097
   PubMed Web of Science ®Google Scholar
• Salle R, Chasset F, Kottler D, et al. Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients. J Am Acad Dermatol. 2020;83(6):1816–1819. doi:10.1016/j.jaad.2020.05.058
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi:10.1056/NEJMoa1912196
   PubMed Web of Science ®Google Scholar
• Khanna U, Galimberti F, Li Y, Fernandez AP. Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening?. Ann Transl Med. 2021;9(5):432. doi:10.21037/atm-20-5215
   PubMed Web of Science ®Google Scholar
• Kuo CF, See LC, Yu KH, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol. 2011;165(6):1273–1279. doi:10.1111/j.1365-2133.2011.10595.x
   PubMed Web of Science ®Google Scholar
• Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339–353. doi:10.1007/s40257-020-00502-6
   PubMed Web of Science ®Google Scholar
• Qudsiya Z, Waseem M. Dermatomyositis. StatPearls Publishing; 2022. Available from:. http://www.ncbi.nlm.nih.gov/books/NBK558917/. Accessed May 31, 2022.
   Google Scholar
• Tansley SL, McHugh NJ, Wedderburn LR. Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?. Arthritis Res Ther. 2013;15(2):211. doi:10.1186/ar4198
   PubMed Web of Science ®Google Scholar
• Vleugels RA. Cutaneous dermatomyositis in adults: overview and initial management - UpToDate. UpToDate; 2021. Available from: https://www.uptodate.com/contents/cutaneous-dermatomyositis-in-adults-overview-and-initial-management?search=dermatomyositis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H423773352. Accessed May 31, 2022.
   Google Scholar
• Diagnostic criteria for Dermatomyositis. The Myositis Association. Available from: https://www.myositis.org/about-myositis/diagnosis/diagnostic-criteria/diagnostic-criteria-for-dermatomyositis/. Accessed May 31, 2022.
   Google Scholar
• Manfredi A, Sebastiani M, Cassone G, et al. Nailfold capillaroscopic changes in dermatomyositis and polymyositis. Clin Rheumatol. 2015;34(2):279–284. doi:10.1007/s10067-014-2795-8
   PubMed Web of Science ®Google Scholar
• Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol. 2007;156(1):191–192. doi:10.1111/j.1365-2133.2006.07595.x
   PubMed Web of Science ®Google Scholar
• Anyanwu CO, Fiorentino DF, Chung L, et al. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173(4):969–974. doi:10.1111/bjd.13915
   PubMed Web of Science ®Google Scholar
• Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434–444. doi:10.1002/art.10561
   PubMed Web of Science ®Google Scholar
• Hoesly PM, Sluzevich JC, Jambusaria-Pahlajani A, Lesser ER, Heckman MG, Abril A. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis. J Am Acad Dermatol. 2019;80(5):1364–1370. doi:10.1016/j.jaad.2018.11.023
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391–398. doi:10.1001/archdermatol.2011.52
   PubMedGoogle Scholar
• Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol. 2007;57(6):937–943. doi:10.1016/j.jaad.2007.08.024
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. J Am Acad Dermatol. 2002;46(4):626–636. doi:10.1067/mjd.2002.120621
   PubMed Web of Science ®Google Scholar
• Sun KY, Fan Y, Wang YX, Zhong YJ, Wang GF. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020. Semin Arthritis Rheum. 2021;51(1):175–191. doi:10.1016/j.semarthrit.2020.11.009
   PubMed Web of Science ®Google Scholar
• Morganroth PA, Kreider ME, Okawa J, Taylor L, Werth VP. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol. 2010;146(7):729–738. doi:10.1001/archdermatol.2010.134
   PubMedGoogle Scholar
• Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85(1):41–45. doi:10.1054/bjoc.2001.1699
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363–367. doi:10.1056/NEJM199202063260602
   PubMed Web of Science ®Google Scholar
• Hsu JL, Liao MF, Chu CC, et al. Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Rep. 2021;11(1):4545. doi:10.1038/s41598-021-83729-5
   PubMed Web of Science ®Google Scholar
• Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther. 2010;12(2):R70. doi:10.1186/ar2987
   PubMed Web of Science ®Google Scholar
• Targoff I. Malignancy in dermatomyositis and polymyositis. UpToDate; 2021. Available from: https://www.uptodate.com/contents/malignancy-in-dermatomyositis-and-polymyositis?search=malignancy%20in%20myositis%20&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H86591283. Accessed October 20, 2022
   Google Scholar
• Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts. Medicine. 2018;97(2):e9639. doi:10.1097/MD.0000000000009639
   PubMed Web of Science ®Google Scholar
• Vaughan H, Rugo HS, Haemel A. Risk-based screening for cancer in patients with dermatomyositis: toward a more individualized approach. JAMA Dermatol. 2022;158(3):244–247. doi:10.1001/jamadermatol.2021.5841
   PubMed Web of Science ®Google Scholar
• Bax CE, Maddukuri S, Ravishankar A, Pappas-Taffer L, Werth VP. Environmental triggers of dermatomyositis: a narrative review. Ann Transl Med. 2021;9(5):434. doi:10.21037/atm-20-3719
   PubMed Web of Science ®Google Scholar
• Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res. 2010;62(2):219–225. doi:10.1002/acr.20071
   PubMed Web of Science ®Google Scholar
• Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10(4):592–600. doi:10.1016/s0190-9622(84)80263-7
   PubMed Web of Science ®Google Scholar
• Pinard J, Femia AN, Roman M, et al. Systemic treatment for clinically amyopathic dermatomyositis at 4 tertiary care centers. JAMA Dermatol. 2019;155(4):494–496. doi:10.1001/jamadermatol.2018.5215
   PubMed Web of Science ®Google Scholar
• Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36(1):67–71. doi:10.1016/s0190-9622(97)70327-x
   PubMed Web of Science ®Google Scholar
• Vencovský J, Jarosová K, Machácek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95–102. doi:10.1080/030097400750001897
   PubMed Web of Science ®Google Scholar
• Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142(1):65–69. doi:10.1001/archderm.142.1.65
   PubMed Web of Science ®Google Scholar
• Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82(2):283–296. doi:10.1016/j.jaad.2019.05.105
   PubMed Web of Science ®Google Scholar
• Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62(10):1496–1501. doi:10.1002/acr.20212
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Charles-Schoeman C, Schessl J, et al. Op0008 a randomized, double-blind, placebo-controlled phase iii trial of Ivig 10% in patients with dermatomyositis. The Proderm Study: results on efficacy and safety. Ann Rheum Dis. 2021;80(Suppl1):4–5. doi:10.1136/annrheumdis-2021-eular.1389
   Web of Science ®Google Scholar
• Paudyal A, Zheng M, Lyu L, et al. JAK-inhibitors for dermatomyositis: a concise literature review. Dermatol Ther. 2021;34(3):e14939. doi:10.1111/dth.14939
   PubMed Web of Science ®Google Scholar
• Kurtzman DJB, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944–945. doi:10.1001/jamadermatol.2016.0866
   PubMed Web of Science ®Google Scholar
• Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol Hoboken NJ. 2021;73(5):858–865. doi:10.1002/art.41602
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291–293. doi:10.1056/NEJMc1900045
   PubMed Web of Science ®Google Scholar
• Konishi R, Tanaka R, Inoue S, Ichimura Y, Nomura T, Okiyama N. Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: a phase 1b clinical trial. J Dermatol. 2022;49(1):118–123. doi:10.1111/1346-8138.16179
   PubMed Web of Science ®Google Scholar
• Chandra T, Aggarwal R. Clinical trials and novel therapeutics in dermatomyositis. Expert Opin Emerg Drugs. 2020;25(3):213–228. doi:10.1080/14728214.2020.1787985
   PubMed Web of Science ®Google Scholar
• Pfizer. A phase 2 double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of pf-06823859 in adult subjects with dermatomyositis; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03181893. Accessed June 9, 2022.
   Google Scholar
• Kilgore C. Lenabasum Improved Skin Symptoms, in Small Dermatomyositis Trial. Medscape. Available from: http://www.medscape.com/viewarticle/974012. Accessed June 10, 2022.
   Google Scholar
• Corbus Pharmaceuticals Inc. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03813160. Accessed June 9, 2022.
   Google Scholar
• Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018;32(2):223–240. doi:10.1016/j.berh.2018.08.005
   PubMed Web of Science ®Google Scholar
• Varga J. Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate; 2022. Available from: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-systemic-sclerosis-scleroderma-in-adults?search=systemic%20sclerosis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H3899918791. Accessed October 20, 2022
   Google Scholar
• Morgan ND, Shah AA, Mayes MD, et al. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: analysis of the genome research in African American scleroderma patients clinical database. Medicine. 2017;96(51):e8980. doi:10.1097/MD.0000000000008980
   PubMed Web of Science ®Google Scholar
• Peoples C, Medsger TA, Lucas M, Rosario BL, Feghali-Bostwick CA. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord. 2016;1(2):177–240. doi:10.5301/jsrd.5000209
   PubMed Web of Science ®Google Scholar
• Adigun R, Goyal A, Hariz A. Systemic sclerosis. StatPearls Publishing; 2022. Available from:. http://www.ncbi.nlm.nih.gov/books/NBK430875/. Accessed May 15, 2022.
   Google Scholar
• Varga J. Risk factors for and possible causes of systemic sclerosis (scleroderma). UpToDate; 2021. Available from: https://www.uptodate.com/contents/risk-factors-for-and-possible-causes-of-systemic-sclerosis-scleroderma?topicRef=7554&source=see_link#H2. Accessed October 20, 2022
   Google Scholar
• Kassamali B, Kassamali AA, Muntyanu A, Netchiporouk E, Vleugels RA, LaChance A. Geographic distribution and environmental triggers of systemic sclerosis cases from 2 large academic tertiary centers in Massachusetts. J Am Acad Dermatol. 2022;86(4):925–927. doi:10.1016/j.jaad.2021.03.055
   PubMed Web of Science ®Google Scholar
• Fox RI, Kang HI. Genetic and environmental factors in systemic sclerosis. Curr Opin Rheumatol. 1992;4(6):857–861.
   PubMedGoogle Scholar
• van den Hoogen F, Khanna D, Fransen J, et al. Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative. Arthritis Rheum. 2013;65(11):2737–2747. doi:10.1002/art.38098
   PubMed Web of Science ®Google Scholar
• Amin K, Clarke A, Sivakumar B, et al. The psychological impact of facial changes in scleroderma. Psychol Health Med. 2011;16(3):304–312. doi:10.1080/13548506.2010.540250
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet Lond Engl. 2017;390(10103):1685–1699. doi:10.1016/S0140-6736(17)
   PubMed Web of Science ®Google Scholar
• Marangoni RG, Rocha LF, Del Rio APT, Yoshinari NH, Marques-Neto JF, Sampaio-Barros PD. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort. Rheumatology. 2013;52(8):1520–1524. doi:10.1093/rheumatology/ket163
   PubMed Web of Science ®Google Scholar
• Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology. 2008;47(8):1185–1192. doi:10.1093/rheumatology/ken179
   PubMed Web of Science ®Google Scholar
• Balbir-Gurman A, Braun-Moscovici Y. Scleroderma overlap syndrome. Isr Med Assoc J IMAJ. 2011;13(1):14–20.
   PubMed Web of Science ®Google Scholar
• Sinnathurai P, Schrieber L. Treatment of Raynaud phenomenon in systemic sclerosis. Intern Med J. 2013;43(5):476–483. doi:10.1111/imj.12082
   PubMed Web of Science ®Google Scholar
• Hutchinson D, Moots RJ. Late onset Raynaud’s phenomenon, hypertension, deteriorating renal function, and a fit in a middle aged woman. Postgrad Med J. 2001;77(914):e10–e10. doi:10.1136/pgmj.77.914.e10
   PubMedGoogle Scholar
• Sulli A, Paolino S, Pizzorni C, et al. Progression of nailfold capillaroscopic patterns and correlation with organ involvement in systemic sclerosis: a 12 year study. Rheumatology. 2020;59(5):1051–1058. doi:10.1093/rheumatology/kez374
   PubMed Web of Science ®Google Scholar
• Mihai C, Smith V, Dobrota R, Gheorghiu AM, Cutolo M, Distler O. The emerging application of semi-quantitative and quantitative capillaroscopy in systemic sclerosis. Microvasc Res. 2018;118:113–120. doi:10.1016/j.mvr.2018.03.004
   PubMed Web of Science ®Google Scholar
• Lambova S, Hermann W, Muller-Ladner U. Nailfold capillaroscopy - its role in diagnosis and differential diagnosis of microvascular damage in systemic sclerosis. Curr Rheumatol Rev. 2013;9(4):254–260. doi:10.2174/157339710904140417125241
   PubMedGoogle Scholar
• Jacobson R, Agnihothri R, Haemel A. Telangiectases in systemic sclerosis. JAMA Dermatol. 2021;157(4):457. doi:10.1001/jamadermatol.2020.4831
   PubMed Web of Science ®Google Scholar
• Jouvray M, Launay D, Dubucquoi S, et al. Whole-body distribution and clinical association of telangiectases in systemic sclerosis. JAMA Dermatol. 2018;154(7):796–805. doi:10.1001/jamadermatol.2018.0916
   PubMed Web of Science ®Google Scholar
• Palmieri GM, Sebes JI, Aelion JA, et al. Treatment of calcinosis with diltiazem. Arthritis Rheum. 1995;38(11):1646–1654. doi:10.1002/art.1780381117
   PubMed Web of Science ®Google Scholar
• Fuchs D, Fruchter L, Fishel B, Holtzman M, Yaron M. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol. 1986;5(4):527–530.
   PubMed Web of Science ®Google Scholar
• Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol. 2008;144(5):585–587. doi:10.1001/archderm.144.5.585
   PubMedGoogle Scholar
• Baumgartner-Nielsen J, Olesen AB. Treatment of Skin Calcifications with Intra-lesional Injection of Sodium Thiosulphate: a Case Series. Acta Derm Venereol. 2016;96(2):257–258. doi:10.2340/00015555-2206
   PubMed Web of Science ®Google Scholar
• Valenzuela A, Song P, Chung L. Calcinosis in scleroderma. Curr Opin Rheumatol. 2018;30(6):554–561. doi:10.1097/BOR.0000000000000539
   PubMed Web of Science ®Google Scholar
• Singh A, Ambujam S, Varghese A, Vishranth SP, Sadanandan N. Salt-and-pepper appearance: a cutaneous clue for the diagnosis of systemic sclerosis. Indian J Dermatol. 2012;57(5):412. doi:10.4103/0019-5154.100512
   PubMedGoogle Scholar
• Rai VM, Balachandran C. Pseudovitiligo in Systemic Sclerosis. Dermatol Online J. 2005;11(3):41.
   PubMedGoogle Scholar
• Razykov I, Levis B, Hudson M, Baron M, Thombs BD; on behalf of the Canadian Scleroderma Research Group. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. Rheumatology. 2013;52(11):2056–2061. doi:10.1093/rheumatology/ket275
   PubMed Web of Science ®Google Scholar
• Kim HJ. Pruritus in autoimmune connective tissue diseases. Ann Transl Med. 2021;9(5):441. doi:10.21037/atm-20-4894
   PubMed Web of Science ®Google Scholar
• Hachulla E, Agard C, Allanore Y, et al. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis. 2021;16(2):322. doi:10.1186/s13023-021-01844-y
   PubMed Web of Science ®Google Scholar
• Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol. 1989;28(4):281–286. doi:10.1093/rheumatology/28.4.281
   PubMedGoogle Scholar
• Turner R, Lipshutz W, Miller W, Rittenberg G, Schumacher HR, Cohen S. Esophageal dysfunction in collagen disease. Am J Med Sci. 1973;265(3):191–199. doi:10.1097/00000441-197303000-00002
   PubMed Web of Science ®Google Scholar
• Kaye-Barrett S, Denton C. Gastrointestinal manifestations of systemic sclerosis (scleroderma). UpToDate; April 15, 2022. Available from: https://www.uptodate.com/contents/gastrointestinal-manifestations-of-systemic-sclerosis-scleroderma?topicRef=7539&source=see_link#H1. Accessed October 20, 2022
   Google Scholar
• Jimenez S. Scleroderma Workup: approach Considerations, Laboratory Studies, Autoantibodies. Medscape; 2022. Available from: https://emedicine.medscape.com/article/331864-workup#c1. Accessed August 5, 2022.
   Google Scholar
• Vonk MC. Is there still a role for cyclophosphamide in the treatment of systemic sclerosis?. J Scleroderma Relat Disord. 2021;6(2):117–122. doi:10.1177/2397198320961673
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2016;4(9):708–719. doi:10.1016/S2213-2600(16)30152-7
   PubMed Web of Science ®Google Scholar
• Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31(2 Suppl 76):151–156.
   PubMed Web of Science ®Google Scholar
• Levy Y, Sherer Y, Langevitz P, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report. Clin Rheumatol. 2000;19(3):207–211. doi:10.1007/s100670050158
   PubMed Web of Science ®Google Scholar
• Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatol Oxf Engl. 2016;55(1):115–119. doi:10.1093/rheumatology/kev318
   PubMed Web of Science ®Google Scholar
• Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3(7):e489–e497. doi:10.1016/S2665-9913(21)
   Google Scholar
• van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364–372. doi:10.1093/rheumatology/35.4.364
   PubMedGoogle Scholar
• Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–1358. doi:10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Allanore Y. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. Arthritis Res Ther. 2021;23(1):155. doi:10.1186/s13075-021-02536-5
   PubMed Web of Science ®Google Scholar
• Allanore Y, Wung P, Soubrane C, et al. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020;79(12):1600–1607. doi:10.1136/annrheumdis-2020-218447
   PubMed Web of Science ®Google Scholar
• Spiera R, Hummers L, Chung L, et al. Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis Rheumatol. 2020;72(8):1350–1360. doi:10.1002/art.41294
   PubMed Web of Science ®Google Scholar
• Hughes M, Allanore Y, Chung L, Pauling JD, Denton CP, Matucci-Cerinic M. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol. 2020;16(4):208–221. doi:10.1038/s41584-020-0386-4
   PubMed Web of Science ®Google Scholar
• Fernández-Codina A, Walker KM, Pope JE; Group the SA. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol. 2018;70(11):1820–1828. doi:10.1002/art.40560
   PubMed Web of Science ®Google Scholar
• Bello RJ, Cooney CM, Melamed E, et al. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud’s Phenomenon: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol Hoboken NJ. 2017;69(8):1661–1669. doi:10.1002/art.40123
   PubMed Web of Science ®Google Scholar
• Shenavandeh S, Sepaskhah M, Dehghani S, Nazarinia M. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis. Clin Rheumatol. 2022;41(1):95–104. doi:10.1007/s10067-021-05900-7
   PubMed Web of Science ®Google Scholar
• Landry GJ. Current medical and surgical management of Raynaud’s syndrome. J Vasc Surg. 2013;57(6):1710–1716. doi:10.1016/j.jvs.2013.03.012
   PubMed Web of Science ®Google Scholar
• Wigley F. Treatment of Raynaud phenomenon: refractory or progressive ischemia - UpToDate. Available from: https://www.uptodate.com/contents/treatment-of-raynaud-phenomenon-refractory-or-progressive-ischemia?search=raynaud%20treatment&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2. Accessed September 11, 2022.
   Google Scholar
• Frech T, Novak K, Revelo MP, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol. 2011;2011:804296. doi:10.1155/2011/804296
   PubMedGoogle Scholar
• Dilia G, Michele C, Emanuele C, Amelia S, Federica L, Clodoveo F. From Localized Scleroderma to Systemic Sclerosis: coexistence or Possible Evolution. Dermatol Res Pract. 2018;2018:1284687. doi:10.1155/2018/1284687
   PubMed Web of Science ®Google Scholar
• Fett NM. Morphea (Localized Scleroderma). JAMA Dermatol. 2013;149(9):1124. doi:10.1001/jamadermatol.2013.5079
   PubMedGoogle Scholar
• LaChance AH, Goldman N, Kassamali B, Vleugels RA. Immunologic underpinnings and treatment of morphea. Expert Rev Clin Immunol. 2022;1–23. doi:10.1080/1744666X.2022.2063841
   Web of Science ®Google Scholar
• Penmetsa GK, Sapra A. Morphea. StatPearls Publishing; 2022. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559010/. Accessed May 8, 2022.
   Google Scholar
• Sapra A, Dix R, Bhandari P, Mohammed A, Ranjit E. A Case of Extensive Debilitating Generalized Morphea. Cureus. 2020;12(5):e8117. doi:10.7759/cureus.8117
   PubMed Web of Science ®Google Scholar
• Morphea: background, Pathophysiology, Etiology; 2021. Available from: https://emedicine.medscape.com/article/1065782-overview#a5. Accessed May 8, 2022.
   Google Scholar
• Jacobe H. Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults - UpToDate. Available from: https://www.uptodate.com/contents/pathogenesis-clinical-manifestations-and-diagnosis-of-morphea-localized-scleroderma-in-adults?search=morphea&source=search_result&selectedTitle=1~54&usage_type=default&display_rank=1#H16539105. Accessed May 12, 2022.
   Google Scholar
• Rodríguez-Salgado P, García-Romero MT. Morphea: a practical review of its diagnosis, classification and treatment. Gac Med Mex. 2019;155(5):483–491. doi:10.24875/GMM.M20000336
   PubMed Web of Science ®Google Scholar
• Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–613. doi:10.1097/01.bor.0000245727.40630.c3
   PubMed Web of Science ®Google Scholar
• Kunzler E, Florez-Pollack S, Teske N, O’Brien J, Prasad S, Jacobe H. Linear morphea: clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort. J Am Acad Dermatol. 2019;80(6):1664–1670.e1. doi:10.1016/j.jaad.2019.01.050
   PubMed Web of Science ®Google Scholar
• Wu EY, Li SC, Torok KS, et al. Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. ACR Open Rheumatol. 2019;1(2):119–124. doi:10.1002/acr2.1019
   PubMedGoogle Scholar
• Helfgott S, Varga J. Eosinophilic fasciitis. UpToDate; 2022. Available from: https://www.uptodate.com/contents/eosinophilic-fasciitis?search=eosinophilic%20fasciitis&source=search_result&selectedTitle=1~74&usage_type=default&display_rank=1#H1. Accessed October 20, 2022
   Google Scholar
• Primitivo A, Madeira N, Lopez D, Afonso D. Eosinophilic fasciitis (Shulman disease) with clinical, imaging and pathological correlation. BMJ Case Rep CP. 2021;14(12):e246151. doi:10.1136/bcr-2021-246151
   PubMedGoogle Scholar
• Mazori DR, Femia AN, Vleugels RA. Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment. Curr Rheumatol Rep. 2017;19(12):74. doi:10.1007/s11926-017-0700-6
   PubMed Web of Science ®Google Scholar
• Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988;17(4):221–231. doi:10.1016/0049-0172(88)90008-x
   PubMed Web of Science ®Google Scholar
• Mazori DR, Kassamali B, Min MS, et al. Characteristics and Outcomes of Eosinophilic Fasciitis-Associated Monoclonal Gammopathy. JAMA Dermatol. 2021;157(12):1508–1509. doi:10.1001/jamadermatol.2021.4302
   PubMed Web of Science ®Google Scholar
• Kreuter A, Wischnewski J, Terras S, Altmeyer P, Stücker M, Gambichler T. Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol. 2012;67(6):1157–1162. doi:10.1016/j.jaad.2012.04.003
   PubMed Web of Science ®Google Scholar
• Lutz V, Francès C, Bessis D, et al. High frequency of genital lichen sclerosus in a prospective series of 76 patients with morphea: toward a better understanding of the spectrum of morphea. Arch Dermatol. 2012;148(1):24–28. doi:10.1001/archdermatol.2011.305
   PubMedGoogle Scholar
• Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70(11):1068–1076. doi:10.4065/70.11.1068
   PubMed Web of Science ®Google Scholar
• Walker D, Susa JS, Currimbhoy S, Jacobe H. Histopathological changes in morphea and their clinical correlates: results from the Morphea in Adults and Children Cohort (MAC) V. J Am Acad Dermatol. 2017;76(6):1124–1130. doi:10.1016/j.jaad.2016.12.020
   PubMed Web of Science ®Google Scholar
• Khatri S, Torok KS, Mirizio E, Liu C, Astakhova K. Autoantibodies in Morphea: an Update. Front Immunol. 2019;10:548.
   PubMed Web of Science ®Google Scholar
• Lythgoe H, Almeida B, Bennett J, et al. Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management. Pediatr Rheumatol Online J. 2018;16(1):80. doi:10.1186/s12969-018-0295-0
   PubMed Web of Science ®Google Scholar
• Mazori DR, Wright NA, Patel M, et al. Characteristics and treatment of adult-onset linear morphea: a retrospective cohort study of 61 patients at 3 tertiary care centers. J Am Acad Dermatol. 2016;74(3):577–579. doi:10.1016/j.jaad.2015.09.069
   PubMed Web of Science ®Google Scholar
• Dytoc MT, Kossintseva I. First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol. 2007;157(3):615–618. doi:10.1111/j.1365-2133.2007.07971.x
   PubMed Web of Science ®Google Scholar
• Jacobe H. Morphea (localized scleroderma) in adults: management - UpToDate. Available from: https://www.uptodate.com/contents/morphea-localized-scleroderma-in-adults-management?search=morphea%20treatment&source=search_result&selectedTitle=1~53&usage_type=default&display_rank=1#H4104427084. Accessed May 10, 2022.
   Google Scholar
• Kroft EBM, Groeneveld TJ, Seyger MMB, De Jong EMGJ. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009;10(3):181–187. doi:10.2165/00128071-200910030-00004
   PubMed Web of Science ®Google Scholar
• Cunningham BB, Landells ID, Langman C, Sailer DE, Paller AS. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998;39(2 Pt 1):211–215. doi:10.1016/s0190-9622(98)
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. Best Pract Res Clin Rheumatol. 2004;18(3):429–462. doi:10.1016/j.berh.2004.03.003
   PubMed Web of Science ®Google Scholar
• Morphea Treatment & Management: medical Care, Surgical Care, Consultations; 2021. Available from: https://emedicine.medscape.com/article/1065782-treatment#d7. Accessed May 11, 2022.
   Google Scholar
• Arthur M, Fett NM, Latour E, et al. Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea. JAMA Dermatol. 2020;156(5):1–8. doi:10.1001/jamadermatol.2020.0035
   PubMed Web of Science ®Google Scholar
• Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006. doi:10.1002/art.30264
   PubMed Web of Science ®Google Scholar
• Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67(6):1151–1156. doi:10.1016/j.jaad.2012.03.036
   PubMed Web of Science ®Google Scholar
• Platsidaki E, Tzanetakou V, Kouris A, Stavropoulos PG. Methotrexate: an effective monotherapy for refractory generalized morphea. Clin Cosmet Investig Dermatol. 2017;10:165–169. doi:10.2147/CCID.S134879
   PubMed Web of Science ®Google Scholar
• Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed High-Dose Corticosteroids Combined With Low-Dose Methotrexate in Severe Localized Scleroderma. Arch Dermatol. 2005;141(7):847–852. doi:10.1001/archderm.141.7.847
   PubMedGoogle Scholar
• Zulian F, Culpo R, Sperotto F, et al. Consensus-based recommendations for the management of juvenile localised scleroderma. Ann Rheum Dis. 2019;78(8):1019–1024. doi:10.1136/annrheumdis-2018-214697
   PubMed Web of Science ®Google Scholar
• Kromer C, Mitterlechner L, Langer N, Schön MP, Mössner R. Response of recalcitrant generalized morphea to intravenous immunoglobulins (IVIg): three cases and a review of the literature. Eur J Dermatol. 2021;31(6):822–829. doi:10.1684/ejd.2021.4173
   PubMed Web of Science ®Google Scholar
• Tkachenko E, Steuer AB, Lo K, et al. Intravenous Immunoglobulin for Refractory Eosinophilic Fasciitis: a Retrospective Analysis from 3 Tertiary Care Centers. J Am Acad Dermatol. 2019;1:S0190. doi:10.1016/j.jaad.2019.12.022
   Google Scholar
• Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA. Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep. 2018;4(5):443–445. doi:10.1016/j.jdcr.2017.12.003
   PubMedGoogle Scholar
• Scheinberg M, Sabbagh C, Ferreira S, Michalany N. Full histological and clinical regression of morphea with tofacitinib. Clin Rheumatol. 2020;39(9):2827–2828. doi:10.1007/s10067-020-05118-z
   PubMed Web of Science ®Google Scholar
• Damsky W, Patel D, Garelli CJ, et al. Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea. J Invest Dermatol. 2020;140(7):1446–1449.e4. doi:10.1016/j.jid.2019.12.019
   PubMed Web of Science ®Google Scholar
• Eming S A Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma; 2021. Available from: Available from: https://clinicaltrials.gov/ct2/show/NCT04200755. Accessed May 12, 2022.
   Google Scholar
• Li SC, Torok KS, Ishaq SS, et al. Preliminary evidence on Abatacept safety and efficacy in refractory juvenile localized scleroderma. Rheumatol Oxf Engl. 2021;60(8):3817–3825. doi:10.1093/rheumatology/keaa873
   PubMed Web of Science ®Google Scholar
• Adeeb F, Anjum S, Hodnett P, et al. Early- and late-stage morphea subtypes with deep tissue involvement is treatable with Abatacept (Orencia). Semin Arthritis Rheum. 2017;46(6):775–781. doi:10.1016/j.semarthrit.2016.08.018
   PubMed Web of Science ®Google Scholar
• Fage SW, Arvesen KB, Olesen AB. Abatacept Improves Skin-score and Reduces Lesions in Patients with Localized Scleroderma: a Case Series. Acta Derm Venereol. 2018;98(4):465–466. doi:10.2340/00015555-2878
   PubMed Web of Science ®Google Scholar
• Localized Fibrosing Disorders - Linear Scleroderma, Morphea, and Regional Fibrosis Treatment & Management: approach Considerations, Medical Care, Surgical Care; 2021. Available from: https://emedicine.medscape.com/article/334939-treatment#d8. Accessed May 29, 2022.
   Google Scholar
• Chen Z, Hu W, Wang Y, Guo Z, Sun L, Kuwana M. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clin Rheumatol. 2015;34(9):1627–1631. doi:10.1007/s10067-015-2935-9
   PubMed Web of Science ®Google Scholar
• Wolstencroft PW, Fiorentino DF. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies. Curr Rheumatol Rep. 2018;20(5):28. doi:10.1007/s11926-018-0733-5
   PubMed Web of Science ®Google Scholar
• Srivastava P, Dwivedi S, Misra R. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Rheumatol Int. 2016;36(7):935–943. doi:10.1007/s00296-016-3494-3
   PubMed Web of Science ®Google Scholar
• Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF. Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients. Arthritis Care Res. 2017;69(12):1909–1914. doi:10.1002/acr.23210
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PloS One. 2013;8(4):e60442. doi:10.1371/journal.pone.0060442
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72(3):449–455. doi:10.1016/j.jaad.2014.12.009
   PubMed Web of Science ®Google Scholar
• Tartar DM, Chung L, Fiorentino DF. Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis. Clin Dermatol. 2018;36(4):508–524. doi:10.1016/j.clindermatol.2018.04.008
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64(2):513–522. doi:10.1002/art.33403
   PubMed Web of Science ®Google Scholar
• Albayda J, Mecoli C, Casciola-Rosen L, et al. A North American Cohort of Anti-SAE Dermatomyositis: clinical Phenotype, Testing, and Review of Cases. ACR Open Rheumatol. 2021;3(5):287–294. doi:10.1002/acr2.11247
   PubMedGoogle Scholar
• Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68(10):1621–1625. doi:10.1136/ard.2008.097162
   PubMed Web of Science ®Google Scholar